anti-EGFR-bispecific antibody armed activated T-cells for Pancreatic Cancer

Phase-Based Progress Estimates
Pancreatic Cancer+3 Moreanti-EGFR-bispecific antibody armed activated T-cells - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new cancer treatment to see if it is safe and effective for people with advanced pancreatic cancer.

Eligible Conditions
  • Pancreatic Cancer
  • Pancreatic Adenocarcinoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 1 year

1 year
Evaluate toxicity

Trial Safety

Trial Design

1 Treatment Group

Pancreatic Adenocarcinoma
1 of 1

Experimental Treatment

7 Total Participants · 1 Treatment Group

Primary Treatment: anti-EGFR-bispecific antibody armed activated T-cells · No Placebo Group · Phase 1

Pancreatic Adenocarcinoma
Experimental Group · 1 Intervention: anti-EGFR-bispecific antibody armed activated T-cells · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year

Who is running the clinical trial?

University of VirginiaOTHER
689 Previous Clinical Trials
1,464,381 Total Patients Enrolled
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,834 Previous Clinical Trials
588,356 Total Patients Enrolled
Kenneth Yu, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have metastatic pancreatic cancer and have received at least first line chemotherapy
You have a platelet count of at least 75,000/mm^3.
Creatinine is less than 2.0 mg/dl
Total bilirubin is greater than 2 mg/dl.

Who else is applying?

What state do they live in?
New York20.0%
How old are they?
18 - 65100.0%
What site did they apply to?
University of Virginia (Specimen Analysis)100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%